Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1954 2
1955 1
1957 1
1958 3
1959 1
1960 3
1962 1
1963 1
1964 2
1966 2
1967 2
1968 5
1969 2
1970 4
1971 3
1972 3
1973 7
1974 5
1975 3
1976 5
1977 6
1978 6
1980 2
1981 3
1982 2
1983 3
1984 3
1985 7
1986 8
1987 7
1988 4
1989 3
1990 3
1991 3
1992 2
1993 1
1994 2
1995 2
1996 4
1997 2
1998 6
1999 5
2000 3
2001 2
2002 2
2003 2
2004 3
2005 4
2006 2
2008 1
2010 2
2011 2
2012 5
2013 1
2014 1
2015 1
2016 1
2017 1
2018 1
2019 1
2021 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
Multiple sclerosis mimics.
Herndon RM. Herndon RM. Adv Neurol. 2006;98:161-6. Adv Neurol. 2006. PMID: 16400833 Review.
Viral infections and demyelinating diseases.
Weiner LP, Johnson RT, Herndon RM. Weiner LP, et al. Among authors: herndon rm. N Engl J Med. 1973 May 24;288(21):1103-10. doi: 10.1056/NEJM197305242882106. N Engl J Med. 1973. PMID: 4348989 Review. No abstract available.
Biotech leaders call for free press.
Cohen R, Holtzman S, Levin JM, Maraganore JM; Signatories to the Statement. Cohen R, et al. Nat Biotechnol. 2018 Oct 11;36(10):920-922. doi: 10.1038/nbt.4271. Nat Biotechnol. 2018. PMID: 30307914 No abstract available.
Advances in specific therapy for multiple sclerosis.
Jacobs L, Goodkin DE, Rudick RA, Herndon R. Jacobs L, et al. Among authors: herndon r. Curr Opin Neurol. 1994 Jun;7(3):250-4. doi: 10.1097/00019052-199406000-00012. Curr Opin Neurol. 1994. PMID: 8081519 Review.
Drug treatment of multiple sclerosis.
Rudick RA, Schiffer RB, Herndon RM. Rudick RA, et al. Among authors: herndon rm. Semin Neurol. 1987 Jun;7(2):150-9. doi: 10.1055/s-2008-1041415. Semin Neurol. 1987. PMID: 2845549 Review. No abstract available.
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.
Giovannoni G, Cutter G, Sormani MP, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott CAM, Ciccarelli O, Selwood D, di Cantogno EV, Ben-Amor AF, Matthews P, Carassiti D, Baker D, Schmierer K. Giovannoni G, et al. Among authors: herndon r. Mult Scler Relat Disord. 2017 Feb;12:70-78. doi: 10.1016/j.msard.2017.01.007. Epub 2017 Jan 17. Mult Scler Relat Disord. 2017. PMID: 28283111 Free article. Review.
The companion.
Herndon RF. Herndon RF. JAMA. 1984 Jun 8;251(22):2926. JAMA. 1984. PMID: 6716613 No abstract available.
Movement disorders in multiple sclerosis.
Mao CC, Gancher ST, Herndon RM. Mao CC, et al. Among authors: herndon rm. Mov Disord. 1988;3(2):109-16. doi: 10.1002/mds.870030202. Mov Disord. 1988. PMID: 3065639 Review.
177 results